EE05233B1 - (R)-ibuprofeenmetaansulfoonamiidi v?i selle soola kasutamine ravimite valmistamiseks, mis on ette n„htud siiratud elundite isheemia/reperfusiooni kahjustuse „rahoidmiseks v?i raviks - Google Patents

(R)-ibuprofeenmetaansulfoonamiidi v?i selle soola kasutamine ravimite valmistamiseks, mis on ette n„htud siiratud elundite isheemia/reperfusiooni kahjustuse „rahoidmiseks v?i raviks

Info

Publication number
EE05233B1
EE05233B1 EEP200300340A EEP200300340A EE05233B1 EE 05233 B1 EE05233 B1 EE 05233B1 EE P200300340 A EEP200300340 A EE P200300340A EE P200300340 A EEP200300340 A EE P200300340A EE 05233 B1 EE05233 B1 EE 05233B1
Authority
EE
Estonia
Prior art keywords
treatment
salt
financing
ischemia
medicament
Prior art date
Application number
EEP200300340A
Other languages
English (en)
Estonian (et)
Inventor
Bertini Riccardo
Colotta Francesco
Novellini Roberto
Original Assignee
Domp S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Domp S.P.A. filed Critical Domp S.P.A.
Publication of EE200300340A publication Critical patent/EE200300340A/xx
Publication of EE05233B1 publication Critical patent/EE05233B1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
EEP200300340A 2001-02-02 2002-01-30 (R)-ibuprofeenmetaansulfoonamiidi v?i selle soola kasutamine ravimite valmistamiseks, mis on ette n„htud siiratud elundite isheemia/reperfusiooni kahjustuse „rahoidmiseks v?i raviks EE05233B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2001MI000206A ITMI20010206A1 (it) 2001-02-02 2001-02-02 Uso della metansolfonammide di (r)-ibuprofene e dei suoi sali non tossici per la preparazione di medicamenti per il trattamento e la prevenz
PCT/EP2002/000946 WO2002062330A2 (en) 2001-02-02 2002-01-30 Use of (r)-ibuprofen methanesulfonamide and salts thereof in the treatment and prevention of rejection reactions of transplanted organs

Publications (2)

Publication Number Publication Date
EE200300340A EE200300340A (et) 2003-10-15
EE05233B1 true EE05233B1 (et) 2009-12-15

Family

ID=11446717

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300340A EE05233B1 (et) 2001-02-02 2002-01-30 (R)-ibuprofeenmetaansulfoonamiidi v?i selle soola kasutamine ravimite valmistamiseks, mis on ette n„htud siiratud elundite isheemia/reperfusiooni kahjustuse „rahoidmiseks v?i raviks

Country Status (26)

Country Link
US (1) US7560487B2 (cs)
EP (1) EP1355641B1 (cs)
JP (1) JP2004517948A (cs)
KR (1) KR100857898B1 (cs)
CN (1) CN1561205A (cs)
AT (1) ATE304846T1 (cs)
AU (1) AU2002250869B2 (cs)
BR (2) BR0206804A (cs)
CA (1) CA2432432C (cs)
CZ (1) CZ303665B6 (cs)
DE (1) DE60206245T2 (cs)
DK (1) DK1355641T3 (cs)
EE (1) EE05233B1 (cs)
ES (1) ES2248541T3 (cs)
HU (1) HU229070B1 (cs)
IL (1) IL157180A (cs)
IT (1) ITMI20010206A1 (cs)
MX (1) MXPA03006686A (cs)
NO (1) NO334285B1 (cs)
NZ (1) NZ526655A (cs)
PL (1) PL215109B1 (cs)
PT (1) PT1355641E (cs)
RU (1) RU2257895C2 (cs)
SK (1) SK287632B6 (cs)
WO (1) WO2002062330A2 (cs)
ZA (1) ZA200304861B (cs)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1579859T3 (da) * 2004-03-25 2007-04-10 Dompe Pha R Ma Spa Res & Mfg Anvendelse af N-(2-arylpropionyl)-sulfonamider til behandling af rygmarvsskader
CA2607953A1 (en) 2005-05-09 2006-11-16 Tap Pharmaceutical Products, Inc. Methods for treating nephrolithiasis
EP2101761A4 (en) * 2006-11-13 2010-01-27 Takeda Pharmaceuticals North A METHODS FOR PRESERVING RENAL FUNCTION USING XANTHINE OXYDOREDUCTASE INHIBITORS
EP2308484A1 (en) * 2009-10-06 2011-04-13 Dompé S.p.a. Inhibitors of cxcr1/2 as adjuvants in the transplant of pancreatic islets
EP2308485A1 (en) 2009-10-06 2011-04-13 Dompé S.p.a. Sulfonamides for the prevention of diabetes
AU2011299153B2 (en) 2010-09-10 2014-10-30 Takeda Pharmaceuticals U.S.A., Inc. Methods for concomitant treatment of theophylline and febuxostat
US10046002B2 (en) 2013-08-02 2018-08-14 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
US10561676B2 (en) * 2013-08-02 2020-02-18 Syntrix Biosystems Inc. Method for treating cancer using dual antagonists of CXCR1 and CXCR2
CA3055004C (en) * 2017-03-15 2023-10-03 Numares Ag Use of a marker set for determining the risk of kidney rejection

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879283A (en) * 1985-10-03 1989-11-07 Wisconsin Alumni Research Foundation Solution for the preservation of organs
RU2008901C1 (ru) * 1991-03-29 1994-03-15 Донецкий государственный медицинский институт им.М.Горького Способ фармакологической защиты децентрализованной почки
ATE257389T1 (de) * 1992-09-17 2004-01-15 Amgen Inc Pharmazeutische zusammensetzungen mit interleukin-1 inhibitoren
IL110296A (en) * 1993-07-16 1999-12-31 Smithkline Beecham Corp Imidazole compounds process for their preparation and pharmaceutical compositions containing them
JPH08231413A (ja) * 1994-12-29 1996-09-10 Mochida Pharmaceut Co Ltd 臓器障害に基づく疾患の予防・治療剤
IT1303249B1 (it) * 1998-10-23 2000-11-06 Dompe Spa Alcune n-(2-aril-propionil)-solfonammidi e preparazionifarmaceutiche che le contengono.
US6355682B1 (en) * 2001-05-11 2002-03-12 Assa Weinberg Treatment of acute renal failure by administration of N-acetylcysteine

Also Published As

Publication number Publication date
EP1355641B1 (en) 2005-09-21
PL363576A1 (en) 2004-11-29
ES2248541T3 (es) 2006-03-16
WO2002062330A2 (en) 2002-08-15
MXPA03006686A (es) 2004-05-31
EE200300340A (et) 2003-10-15
US7560487B2 (en) 2009-07-14
ATE304846T1 (de) 2005-10-15
PT1355641E (pt) 2005-11-30
DE60206245D1 (de) 2006-02-02
KR20030074725A (ko) 2003-09-19
RU2003126600A (ru) 2005-02-27
IL157180A (en) 2009-06-15
HU229070B1 (hu) 2013-07-29
AU2002250869B2 (en) 2006-10-19
CZ303665B6 (cs) 2013-02-20
RU2257895C2 (ru) 2005-08-10
HUP0303024A3 (en) 2005-07-28
ZA200304861B (en) 2004-06-30
CA2432432C (en) 2008-03-25
NO20033273D0 (no) 2003-07-18
US20040102520A1 (en) 2004-05-27
DK1355641T3 (da) 2005-10-17
NO20033273L (no) 2003-07-18
ITMI20010206A1 (it) 2002-08-02
CN1561205A (zh) 2005-01-05
BR0206804A (pt) 2004-02-03
JP2004517948A (ja) 2004-06-17
CZ20032095A3 (en) 2004-05-12
SK9732003A3 (en) 2003-11-04
SK287632B6 (sk) 2011-04-05
NZ526655A (en) 2005-02-25
BRPI0206804B1 (pt) 2018-09-25
DE60206245T2 (de) 2006-06-14
NO334285B1 (no) 2014-01-27
PL215109B1 (pl) 2013-10-31
KR100857898B1 (ko) 2008-09-10
HUP0303024A2 (hu) 2003-12-29
WO2002062330A3 (en) 2003-04-03
EP1355641A2 (en) 2003-10-29
CA2432432A1 (en) 2002-08-15

Similar Documents

Publication Publication Date Title
BG106825A (en) Substituted oxazolidinones and their use in the field of blood coagulation
DK1235826T3 (da) Quinuclidinacrylamider
NO20035743D0 (no) Substituerte oksazolindinoner for kombinasjonsterapi
ME01222B (me) Nova kombinovana upotreba jedinjenja sulfonamida u liječenju kancera
BRPI0407662B8 (pt) derivados do ácido 1-fenilalcanocarboxílico para o tratamento de doenças neurodegenerativas
CA2436462A1 (en) Inhibitors of cruzipain and other cysteine proteases
EE05233B1 (et) (R)-ibuprofeenmetaansulfoonamiidi v?i selle soola kasutamine ravimite valmistamiseks, mis on ette n„htud siiratud elundite isheemia/reperfusiooni kahjustuse „rahoidmiseks v?i raviks
EP1350511A4 (en) MEDICAL COMPOSITIONS CONTAINING ASPIRIN
EP1197210A4 (en) MEANS TO PREVENT THE CHRONIC BREATHING REACTION AS A RESULT OF AN ORGANTRANSPLANTATION
BR0316085A (pt) Substâcias microbicidas
EP1755576A4 (en) ANTIMICROBIAL COMPOSITIONS AND METHOD OF USE THEREOF
BR0313655A (pt) Uso de n-(3-metóxi-5-metilpirazin-2-il)-2-(4-[1, 3, 4-oxadiazol-2-il]fenil) piridina-3-sulfonamida, ou um sal do mesmo farmaceuticamente aceitável
TR200200473T2 (tr) Rar selektif retinoid agonistleri.
ATE344662T1 (de) Mittel enthaltend n-chlortaurin sowie dessen verwendung zur behandlung von schleimhautpolypen
JP2004517948A5 (cs)
DE602004022783D1 (de) Heterozyklische harnstoff-derivate für die behandlung von schmerzen.
ATE521344T1 (de) Calciumsalze zur behandlung von psoriasis, dermatitis und schuppen
NO20052562L (no) Anvendelse av distrontiumsalter av 2-[N,N-di(karboksylmetyl)amino]-3-cyano-4-karboksylmetyl-tiofen-5-karboksylsyre for fremstilling av medikamenter for behandlingen av gastro-duodenal smerte.
GR1004434B (el) Χρησηατουαdiclofenacαhααποδεκτωνααλατωνααυτουαγιαατηνααντιμετωπισηατωναεγκαυματων
EA200501765A3 (ru) Средство для лечения болезней суставов
ITTO20040343A1 (it) Uso di neboglamine (cr2249) come neuropsicotico e neuroprotettivo
PL1514545T3 (pl) Zastosowanie tolperyzonu do leczenia skurczów narządów zbudowanych zasadniczo z mięśni gładkich
RU2006104187A (ru) Препарат для лечения микозов и гнойной инфекции
UY26502A1 (es) Oxazolidinonas substituidas y su uso

Legal Events

Date Code Title Description
GB1A Change in the ownership or in the address of the owner
KB4A Valid patent at the end of a year

Effective date: 20101231

GB1A Change in the ownership or in the address of the owner
MM4A Lapsed by not paying the annual fees

Effective date: 20200130